MRC Myeloma VII Trial: Standard vs Intensive Treatment for Multiple Myeloma
Author Information
Author(s): Peter Selby, Tony Child, Faith Davies, Kim Hawkins, Julia Brown, Sue Bell, Gareth Morgan
Primary Institution: University of Leeds
Hypothesis
Does intensive treatment with high dose melphalan improve survival in patients with multiple myeloma compared to standard treatment?
Conclusion
Intensive treatment resulted in improved survival compared to standard treatment in patients with multiple myeloma.
Supporting Evidence
- Intensive treatment group had a median survival of 54.1 months.
- Standard treatment group had a median survival of 42.3 months.
- Statistical tests showed significant differences in survival between treatment groups.
Takeaway
This study found that patients with multiple myeloma lived longer when they received a stronger treatment compared to the usual one.
Methodology
A prospective randomised Phase III trial comparing standard treatment with intensive treatment in patients with multiple myeloma.
Limitations
The study may not be generalizable to patients over 65 years of age.
Participant Demographics
Patients were under 65 years of age with multiple myeloma.
Statistical Information
P-Value
0.047
Statistical Significance
p=0.047
Want to read the original?
Access the complete publication on the publisher's website